文献速递母胎医学产科

产前游离DNA筛查性染色体异常的准确性:系统综述与Meta分析

The accuracy of prenatal cell-free DNA screening for sex chromosome abnormalities: A systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-12-24

该系统综述与Meta分析检索至2022年1月,纳入94篇文献共1,531,240例受检孕妇,评估游离DNA筛查性染色体异常的准确性。合并阳性预测值为49.4%(95%CI 45.8-53.1),合并敏感度94.1%、特异度99.5%,汇总受试者工作特征曲线下面积0.934。作者认为敏感度与特异度高但阳性预测值约50%,临床提供该筛查时应告知夫妇这些发现。

要点

  • 游离DNA筛查性染色体异常的合并敏感度为94.1%(95%CI 90.8%-96.3%),合并特异度为99.5%(95%CI 99.0%-99.7%)。
  • 合并阳性预测值为49.4%(95%CI 45.8-53.1),其中单体X为32.0%,XXY为67.6%,XXX为57.5%,XYY为70.9%。
  • 作者认为临床提供游离DNA筛查性染色体异常时应告知夫妇上述阳性预测值发现。

核心结论

  • 游离DNA筛查性染色体异常的敏感度与特异度高,但阳性预测值约为50%。
  • 含额外Y染色体的性染色体异常阳性预测值较高,单体X阳性预测值较低。
  • 作者认为临床提供游离DNA筛查性染色体异常时应告知夫妇这些发现。

研究设计与样本

  • 系统综述与Meta分析,检索Medline与PubMed、Embase及Web of Science自建库至2022年1月。
  • 纳入原创论文、随机对照试验、会议摘要、队列与病例对照研究及病例数超过10例且有诊断确认的病例系列。
  • 共94篇文献纳入Meta分析,累计1,531,240例受检孕妇;所有研究均报告了确诊性基因检测。
  • 采用诊断准确性研究质量评价工具第2版(QUADAS-2)进行质量评价。
  • 阳性预测值按阳性且接受诊断检测者中真阳性比例计算,敏感度与特异度采用双变量模型合并并生成汇总受试者工作特征曲线。

主要发现

  • 检索共获得7553条结果,380篇进入全文筛选,94篇纳入Meta分析。
  • 合并阳性预测值为49.4%(95%CI 45.8-53.1)。
  • 单体X阳性预测值为32.0%(95%CI 27.0%-37.3%),XXY为67.6%(95%CI 62.5%-72.5%),XXX为57.5%(95%CI 51.7%-63.1%),XYY为70.9%(95%CI 63.9%-77.1%)。
  • 合并敏感度为94.1%(95%CI 90.8%-96.3%),合并特异度为99.5%(95%CI 99.0%-99.7%)。
  • 汇总受试者工作特征曲线下面积为0.934(95%CI 0.907-0.989)。

关键数值与推荐

  • 合并阳性预测值49.4%(95%CI 45.8-53.1)。
  • 单体X阳性预测值32.0%(95%CI 27.0%-37.3%),XXY 67.6%(95%CI 62.5%-72.5%),XXX 57.5%(95%CI 51.7%-63.1%),XYY 70.9%(95%CI 63.9%-77.1%)。
  • 合并敏感度94.1%(95%CI 90.8%-96.3%),合并特异度99.5%(95%CI 99.0%-99.7%)。
  • 汇总受试者工作特征曲线下面积0.934(95%CI 0.907-0.989)。

临床怎么用

  • 作者认为临床提供游离DNA筛查性染色体异常时应告知夫妇合并阳性预测值约为50%及不同异常类型阳性预测值存在差异这些发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although cell-free DNA screening for sex chromosome abnormalities is increasingly used in clinical practice, its diagnostic accuracy and clinical utility remain unclear. This systematic review and meta-analysis aimed to determine the performance of cell-free DNA in the detection of sex chromosome abnormalities. DATA SOURCES: Medline and PubMed, Embase, and Web of Science were searched from inception to January 2022 for articles relating to cell-free DNA screening for sex chromosome abnormalities. STUDY ELIGIBILITY CRITERIA: Original articles, randomized control trials, conference abstracts, cohort and case-control studies, and case series with more than 10 cases with diagnostic confirmation were considered for inclusion. METHODS: Quality assessment of each included publication was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. The positive predictive value was calculated as the proportion of true positive cases among those who tested positive and underwent diagnostic testing. Sensitivity and specificity were pooled, and a summary receiver operating characteristic curve was produced using bivariate models that included studies that had diagnostic confirmation for high- and low-risk women. RESULTS: The search identified 7553 results. Of these, 380 proceeded to the full-text screening, of which 94 articles were included in the meta-analysis with a total of 1,531,240 women tested. All studies reported a confirmatory genetic test. The pooled positive predictive value was 49.4% (95% confidence interval, 45.8-53.1). The pooled positive predictive value was 32.0% (95% confidence interval, 27.0%-37.3%) for monosomy X, 67.6% (95% confidence interval, 62.5%-72.5%) for XXY, 57.5% (95% confidence interval, 51.7%-63.1%) for XXX, and 70.9% (95% confidence interval, 63.9%-77.1%) for XYY. The pooled sensitivity and specificity of cell-free DNA for sex chromosome abnormalities were 94.1% (95% confidence interval, 90.8%-96.3%) and 99.5% (95% confidence interval, 99.0%-99.7%), respectively, with an area under the summary receiver operating characteristic curve of 0.934 (95% confidence interval, 0.907-0.989). CONCLUSION: Although the sensitivity and specificity of cell-free DNA for sex chromosome abnormalities are high, the positive predictive value was approximately 50%. The positive predictive value was higher for sex chromosome abnormalities with a supernumerary Y chromosome and lower for monosomy X. Clinicians should inform couples about these findings when offering cell-free DNA for sex chromosome abnormalities.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Bussolaro S, Raymond YC, Acreman ML, et al. The accuracy of prenatal cell-free DNA screening for sex chromosome abnormalities: A systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2022. PMID: 36572107. doi:10.1016/j.ajogmf.2022.100844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。